On July 21, 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or the "Company") reported that its share purchase plan ("SPP"), details of which were announced to ASX on 21 June 2021, closed at 5.00pm on Monday, 19 July 2021 with the Company receiving total SPP application funds of A$7,175,720, exceeding the targeted amount sought to be raised under the SPP of A$5 million (Press release, Immutep, JUL 21, 2021, View Source [SID1234585013]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following strong demand from eligible shareholders who participated in the SPP, Immutep’s board has exercised its discretion to increase the size of the SPP to accept the full amount of applications received from eligible shareholders under the SPP. Accordingly, there will be no scale back of ordinary shares ("Shares") applied for under the SPP, meaning applicants who submitted a valid application will receive the full number of Shares for which they applied.

Accordingly, the Company has raised A$7,175,720 before transaction-related expenses through the SPP. This is in addition to the A$60 million two-tranche institutional placement ("Placement") (details of which were announced to ASX on 21 June 2021) where the issue of Shares under the second tranche of the Placement (representing approximately A$46.3 million) is subject to shareholder approval at the Company’s upcoming EGM to be held on Monday, 26 July 2021.

The funds raised from the SPP and Placement will be used to support Immutep’s ongoing and planned immuno-oncology clinical development programs, its pre-clinical program in autoimmune disease and for general working capital purposes.

The Company expects that 13,799,149 new Shares issued under the SPP will be issued to eligible shareholders on Friday, 23 July 2021 and holding statements will be dispatched by Tuesday, 3 August 2021. The new Shares issued under the SPP are expected to commence trading on the ASX on Monday, 26 July 2021.

The Board of Immutep wishes to thank all shareholders who participated in the SPP.

This announcement was authorised for release by the Board of Immutep Limited.